Gabapentin + Gabapentin + Gabapentin + Gabapentin
ApprovedTerminated 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
PK Properties Of Gabapentin In Subjects With Impaired Renal Function
Conditions
PK Properties Of Gabapentin In Subjects With Impaired Renal Function
Trial Timeline
Oct 1, 2007 → Dec 1, 2007
NCT ID
NCT00584779About Gabapentin + Gabapentin + Gabapentin + Gabapentin
Gabapentin + Gabapentin + Gabapentin + Gabapentin is a approved stage product being developed by Pfizer for PK Properties Of Gabapentin In Subjects With Impaired Renal Function. The current trial status is terminated. This product is registered under clinical trial identifier NCT00584779. Target conditions include PK Properties Of Gabapentin In Subjects With Impaired Renal Function.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00584779 | Approved | Terminated |